Format

Send to

Choose Destination
Alzheimers Dement (Amst). 2015 Oct 9;1(4):403-11. doi: 10.1016/j.dadm.2015.09.002. eCollection 2015 Dec.

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study.

Author information

1
Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Skåne University Hospital, Malmö, Sweden; Memory Clinic, Skåne University Hospital, Malmö, Sweden.
2
Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden; UCL Institute of Neurology, London, UK.
3
Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.

Abstract

INTRODUCTION:

Ascertainment of the pattern and temporal change of biomarkers in preclinical (asymptomatic) sporadic Alzheimer's disease (AD) will increase knowledge about early pathogenesis and facilitate interventional therapeutic trials.

METHODS:

In this prospective longitudinal study, repeated cerebrospinal fluid (CSF) collections and cognitive evaluations were performed in cognitively healthy elderly individuals during a 9-year period.

RESULTS:

Low CSF β-amyloid (Aβ)42 levels predicted subsequent development of clinical AD 9 years later. Noteworthy, one-third of individuals with pathologically low baseline Aβ42 levels remained cognitively intact during follow-up. No further decrease in Aβ42 was seen in those with low levels already at baseline.

DISCUSSION:

CSF Aβ42 predicts sporadic AD at least 9 years before dementia onset and has plateaued already at this time. However, many individuals can harbor brain amyloid accumulation over a decade without signs of cognitive deterioration, which could implicate how CSF biomarkers are used to identify preclinical AD in future interventional therapeutic trials.

KEYWORDS:

Alzheimer's disease; Cerebrospinal fluid; Cognitive aging; Cohort studies; Dementia; Tau protein; β-Amyloid1–42

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center